Rubius Therapeutics’ $200 Million Underwritten Public Offering

Martina Bellini North America, North America Legal Chronicle
Tagged:

Goodwin Procter LLP advised Rubius Therapeutics on the deal.Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at a…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Martina Bellini

Author: Martina Bellini

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here